Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications
Language English Country Germany Media print-electronic
Document type Journal Article, Multicenter Study, Observational Study
PubMed
29080909
DOI
10.1007/s00392-017-1173-3
PII: 10.1007/s00392-017-1173-3
Knihovny.cz E-resources
- Keywords
- B-blockers, Heart failure, Mortality, Potassium, Renal failure,
- MeSH
- Acute Disease MeSH
- Adrenergic beta-Antagonists therapeutic use MeSH
- Biomarkers blood MeSH
- Time Factors MeSH
- Potassium blood MeSH
- Hyperkalemia etiology mortality prevention & control MeSH
- Hypokalemia etiology mortality prevention & control MeSH
- Middle Aged MeSH
- Humans MeSH
- Survival Rate trends MeSH
- Follow-Up Studies MeSH
- Prospective Studies MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Heart Failure blood complications drug therapy MeSH
- Treatment Outcome MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Observational Study MeSH
- Geographicals
- Europe epidemiology MeSH
- United States epidemiology MeSH
- Names of Substances
- Adrenergic beta-Antagonists MeSH
- Biomarkers MeSH
- Potassium MeSH
BACKGROUND: The interaction between chronic medications on admission and the association between serum potassium level and outcome in patients with acute heart failure (AHF) are unknown. METHODS: Observational intercontinental study of patients admitted with AHF. 15954 patients were included from 12 cohorts in 4 continents. Main outcome was 90-day mortality. Clinical presentation (medication use, hemodynamics, comorbidities), demographic, echocardiographic, and biochemical data on admission were recorded prospectively in each cohort, with prospective adjudication of outcomes. RESULTS: Positive and negative linear relationships between 90-day mortality and sK+ above 4.5 mmol/L (hyperkalemia) and below 3.5 mmol/L (hypo-kalemia) were observed. Hazard ratio for death was 1.46 [1.34-1.58] for hyperkalemia and 1.22 [1.06-1.40] for hypokalemia. In a fully adjusted model, only hyperkalemia remained associated with mortality (HR 1.03 [1.02-1.04] for each 0.1 mmol/l change of sK+ above 4.5 mmol/L). Interaction tests revealed that the association between hyperkalemia and outcome was significantly affected by chronic medications. The association between hyperkalemia and mortality was absent for patients treated with beta blockers and in those with preserved renal function. CONCLUSIONS: In patients with AHF, sK+ > 4.5 mmol/L appears to be associated with 90-day mortality. B-blockers have potentially a protective effect in the setting of hyperkalemia.
ANMCO Research Center Firenze Italy
AP HP Groupe Hospitalier Saint Louis Lariboisière Fernand Widal Paris France
Baylor College of Medicine Houston TX USA
Department of Internal Medicine and Cardiology University Hospital Brno Brno Czech Republic
Faculty of Medicine Masaryk University Brno Czech Republic
Nippon Medical School Musashi Kosugi Hospital Kanagawa Japan
Saint Luke's Mid America Heart Institute and University of Missouri Kansas City Kansas MO USA
Sociedad Argentina de Cardiologia Area de Investigacion SAC Azcuenaga Buenos Aires Argentina
See more in PubMed
Clin Res Cardiol. 2017 Sep;106(9):711-721 PubMed
JAMA. 2009 Oct 21;302(15):1658-65 PubMed
Clin J Am Soc Nephrol. 2010 May;5(5):762-9 PubMed
Clin Res Cardiol. 2016 Jun;105(6):489-507 PubMed
Eur J Heart Fail. 2016 Aug;18(8):891-975 PubMed
Kidney Int. 2007 Aug;72(4):397-410 PubMed
J Am Coll Cardiol. 2013 Oct 22;62(17):1585-93 PubMed
J Am Coll Cardiol. 2004 Jan 21;43(2):155-61 PubMed
J Am Coll Cardiol. 2013 Feb 26;61(8):820-9 PubMed
Crit Care Med. 2014 Sep;42(9):2109-17 PubMed
Circ Heart Fail. 2010 Mar;3(2):253-60 PubMed
Am J Cardiol. 2015 Mar 15;115(6):790-6 PubMed
Crit Care Med. 2011 May;39(5):940-4 PubMed
Int J Cardiol. 2014 Dec 20;177(3):731-3 PubMed
Eur Heart J. 2012 Nov;33(22):2782-95 PubMed
N Engl J Med. 2014 Apr 10;370(15):1383-92 PubMed
Int J Cardiol. 2010 Oct 29;144(3):383-8 PubMed
Eur Heart J. 2009 Sep;30(18):2186-92 PubMed
Ann Intern Med. 2012 Jun 5;156(11):767-75, W-261, W-262 PubMed
Clin Res Cardiol. 2017 Nov;106(11):923-932 PubMed
Clin Res Cardiol. 2016 May;105(5):441-50 PubMed
Clin Res Cardiol. 2017 Oct;106(10 ):802-812 PubMed
Eur J Heart Fail. 2017 Feb;19(2):201-208 PubMed
Clin Res Cardiol. 2017 Dec;106(12 ):960-973 PubMed
Eur Heart J. 2007 Jun;28(11):1334-43 PubMed
Int J Cardiol. 2009 Sep 11;137(1):1-8 PubMed